Influenza and Adaptive Immunity

Gunnveig GrødelandGroup leader
Gunnveig Grødeland
Group leader

We perform research related to modulation of adaptive immune responses. Influenza is the key disease model used, and the research includes investigations into both the immunological signatures of vaccine efficacy as well as development of the next generation vaccines against infectious diseases. A challenge is that conventional vaccines fail to elicit protective immunity against highly mutagenic pathogens, or pathogens that have developed mechanisms to thwart the immune system. A main objective for the group is thus to study immunological mechanisms behind protective immunity, and development improved vaccine formats.

About our research in Norwegian


  • Development of an HLAII-targeted DNA vaccine that can rapidly be produced to protect against the emergence of an influenza virus with pandemic potential. This project is performed in collaboration with Bjarne Bogen, and includes clinical Phase I testing of a candidate vaccine against influenza H7N9
  • Investigations into the immunological signatures of obesity, and how these influences vaccine efficacy 
  • The characteristics of broadly protective antibodies against influenza, with an aim of developing the next generation vaccines that can offer broad protection against highly variable viruses such as influenza
  • Development of broadly reactive vaccines based on epitope dilution, where a mixture of different antigens is used to promote formation of protective immune responses against shared regions at the expense of more immunodominant epitopes that are specific only for a particular virus antigen. This is a collaboration with Bjarne Bogen